Completed
Summary
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Cardiac Amyloidosis: An Underdiagnosed, Not Rare Disease - Grand Rounds 15 Feb 2023
Automatically move to the next video in the Classroom when playback concludes
- 1 Welcome
- 2 Black History Month
- 3 Virtual Grand Rounds
- 4 Presentation Mode
- 5 Amyloidosis
- 6 Clinical subtypes
- 7 Path of physiology
- 8 Mechanisms
- 9 Direct Cardiotoxicity
- 10 Molecular Studies
- 11 Treatment
- 12 Early Diagnosis
- 13 Time is of the Essence
- 14 Rochester Minnesota
- 15 Amyloidosis Metaanalysis
- 16 Not Rare
- 17 Diagnosis
- 18 Imaging
- 19 Biopsy
- 20 Mass spectrometry
- 21 Nuclear centigraphy
- 22 Extra cardiac clues
- 23 Screening algorithm
- 24 Why is it important
- 25 What happens in HTTR
- 26 Treatments for HTTR
- 27 Landmark Study
- 28 subgroup analysis
- 29 silencers
- 30 Zynotarsin
- 31 Current FDA labeling
- 32 Clinical trials
- 33 Gene editing
- 34 Challenges
- 35 Treatment Access
- 36 Research
- 37 Summary
- 38 Thank you
- 39 I would say two things
- 40 modalities that are necessary
- 41 machine learning AI
- 42 environmental risk factors
- 43 Amyloidosis and blacks
- 44 Advanced stages of disease
- 45 Finding milder patients
- 46 Safety duration of effect
- 47 Why are beta blockers and ACE inhibitors ineffective
- 48 Are there specific sensitive immune biomarkers being studied
- 49 Do you collect exosome data
- 50 Do you recommend genetic testing
- 51 Is there a treatment
- 52 For primary care doctors
- 53 Closing remarks
